Abstract

Insulin resistance is an underappreciated facet of type 1 diabetes that occurs with remarkable consistency and considerable magnitude. Although therapeutic innovations are continuing to normalize dysglycemia, a sizable body of data suggests a second metabolic abnormality-iatrogenic hyperinsulinemia-principally drives insulin resistance and its consequences in this population and has not been addressed. We review this evidence to show that injecting insulin into the peripheral circulation bypasses first-pass hepatic insulin clearance, which leads to the unintended metabolic consequence of whole-body insulin resistance. We propose restructuring insulin therapy to restore the physiological insulin balance between the hepatic portal and peripheral circulations and thereby avoid the complications of life-long insulin resistance. As technology rapidly advances and our ability to ensure euglycemia improves, iatrogenic insulin resistance will become the final barrier to overcome to restore normal physiology, health, and life in type 1 diabetes.

MeSH

Insulin Resistance, Therapeutics, Diabetes Mellitus, Type 1

Cited by

• Echocardiographic parameters according to insulin dose in young patients affected by type 1 diabetes. PLoS One, 2021
• Glucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer? Front Endocrinol (Lausanne), 2025
• Insulin Resistance in Type 1 Diabetes: Pathophysiological, Clinical, and Therapeutic Relevance. Endocr Rev, 2025
• Importance of the route of insulin delivery to its control of glucose metabolism. Am J Physiol Endocrinol Metab, 2021
• Insulin-mediated muscle microvascular perfusion and its phenotypic predictors in humans. Sci Rep, 2021
• Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility. J Diabetes Sci Technol, 2023
• Streptozotocin-induced Diabetes Represses Hepatic CYP2R1 Expression but Induces Vitamin D 25-Hydroxylation in Male Mice. Endocrinology, 2022
• Insulin resistance in cardiovascular disease, uremia, and peritoneal dialysis. Trends Endocrinol Metab, 2022
• Hyperinsulinemia in Obesity, Inflammation, and Cancer. Diabetes Metab J, 2022
• Profound Sensitivity of the Liver to the Direct Effect of Insulin Allows Peripheral Insulin Delivery to Normalize Hepatic but Not Muscle Glucose Uptake in the Healthy Dog. Diabetes, 2023
• Glycemic control in critically ill patients with or without diabetes. BMC Anesthesiol, 2022
• Diabetes pathogenesis and management: the endothelium comes of age. J Mol Cell Biol, 2022
• Sweeteners: erythritol, xylitol and cardiovascular risk-friend or foe? Cardiovasc Res, 2025
• Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes. JCEM Case Rep, 2023
• Morning Engagement of Hepatic Insulin Receptors Improves Afternoon Hepatic Glucose Disposal and Storage. bioRxiv, 2024
• Acute and Chronic Glucose Control in Critically Ill Patients With Diabetes: The Impact of Prior Insulin Treatment. J Diabetes Sci Technol, 2022
• The Effects of Resistance Exercise Training on Skeletal Muscle Metabolism and Insulin Resistance Development in Female Rodents with Type 1 Diabetes. J Diabetes Res, 2024
• Unveiling the Therapeutic Potential of the Second-Generation Incretin Analogs Semaglutide and Tirzepatide in Type 1 Diabetes and Latent Autoimmune Diabetes in Adults. J Clin Med, 2025
• The Importance of the Mechanisms by Which Insulin Regulates Meal-Associated Liver Glucose Uptake in the Dog. Diabetes, 2021
• CpG methylation changes associated with hyperglycemia in type 1 diabetes occur at angiogenic glomerular and retinal gene loci. Sci Rep, 2025